Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 3
Abstract
Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Material and methods. We evaluated HBV DNA clearance, HBeAg/antiHBe and HBsAg/antiHBs seroconversion rates in HBeAg-positive and negative NUC naïve HBV patients treated with ETV for more than 6 months, and predictors of response. Results. A hundred and sixty nine consecutive patients were treated with ETV for a median of 181 weeks. 61% were HBeAg positive, 23% were cirrhotics, and mean HBV-DNA levels were 6,88 ± 1,74 log10 IU/mL. Overall, 156 (92%) patients became HBV DNA undetectable, 92 (88%) HBeAg positive and 64 (98%) HBeAg negative patients. Seventy four (71%) patients cleared HBeAg after a median of 48 weeks of treatment, 23 (14%) patients cleared HBsAg (19 HBeAg positive and 4 HBeAg negative, p 0.025) after a median of 96 weeks of treatment, and 22 (13%) patients developed protective titers of anti-HBs. At the end of the study, 35 (20%) patients had discontinued therapy: 33 HBeAg positive and 2 HBeAg negative; 9 of them (26%) developed virological relapse after a median of 48 weeks of stopping treatment. None of the patients had primary non response and one patient developed breakthrough. Two patients developed HCC, three underwent liver transplantation and 3 deaths were attributable to liver-related events. No serious adverse events were reported. Conclusion. Long term ETV treatment showed high virological response rates, and a favorable safety profile for NUC-naive HBeAg-positive and negative patients treated in clinical practice.
Authors and Affiliations
Ezequiel Ridruejo, Sebastián Marciano, Omar Galdame, María V. Reggiardo, Alberto E. Muñoz, Raúl Adrover, Daniel Cocozzella, Nora Fernandez, Claudio Estepo, Manuel Mendizabal, Gustavo A. Romero, Diana Levi, Teresa Schroder, Silvia Paz, Hugo Fainboim, Oscar G. Mandó, Adrián C. Gadano, Marcelo O. Silva
Keywords
Related Articles
- EP ID EP78393
- DOI -
- Views 125
- Downloads 0
Hepatic carcinosarcoma: clinicopathologic features and a review of the literature
Hepatic carcinosarcoma (HCS) is defined as a malignant tumor containing an intimate mixture of carcinomatous and sarcomatous elements. Here, we report the case of a 72-year-old man who developed HCS from an otherwise nor...
Portal vein aneurysm: is it an incidental finding only?
Portal vein aneurysms are uncommon incidental imaging findings. They usually do not require any treatment unless symptomatic. Contrast enhanced CT is the imaging modality of choice for depicting its morphology and extens...
Usefulness of liver biopsy in chronic hepatitis C
Major requirements for performance of liver biopsy (LB) are the benefits for the patient and the impossibility of having the same information by less invasive procedures. In the last two decades physicians have faced the...
Liver overload in Brazilian triathletes after half-ironman competition is related muscle fatigue
Triathlon competition is dependent on the athletes’ ability to perform each discipline at optimal time, without excessive fatigue influencing the next one. Objectives: Determine the effects of a long distance triathlon o...
Role of nonalcoholic fatty liver disease in hepatocellular carcinoma
Obesity and related disorders are a common cause of morbidity worldwide. Nonalcoholic fatty liver disease is the most important hepatic consequence of adipose accumulation. There is strong evidence of obesity-related dis...